Clinical Trial Update: Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase II trial of cabazitaxel for refractory metastatic gastric adenocarcinoma and gastroesophageal adenocarcinoma completed; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Distal Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Adenocarcinoma

Drugs mentioned

• Jevtana (cabazitaxel) (cabazitaxel)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-04-03